Dosulepin hydrochloride
Brand names: Prothiaden
Dosulepin is a tricyclic antidepressant historically used for depression, particularly where sedation is desirable.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits the reuptake of noradrenaline and serotonin and has antimuscarinic and antihistaminic actions, contributing to both its antidepressant and sedative effects.
Prescribing in practice
- Dosulepin is particularly dangerous and frequently fatal in overdose, so initiation by non-specialists is discouraged and it should generally be avoided in favour of safer antidepressants.
- It carries pronounced antimuscarinic and cardiotoxic effects and should be avoided in cardiovascular disease, arrhythmias and significant cardiac risk.
- Caution is needed in the elderly, in prostatic hypertrophy, glaucoma and epilepsy because of antimuscarinic effects and a lowered seizure threshold.
Monitoring
Monitor mood, suicidal ideation and cardiac and antimuscarinic adverse effects, especially during initiation and dose change.
Counselling the patient
- Do not take more than prescribed as this drug is very dangerous in overdose.
- May cause drowsiness, dry mouth and blurred vision and can impair driving.
- Continue treatment as directed and do not stop abruptly.
Evidence & guidelines
NICE advises against routine use of dosulepin because of its disproportionate toxicity in overdose compared with other antidepressants.
Reference: NICE NG222; MHRA Drug Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185